Syntekabio Inc.’s Post

 Major Partnerships in AI-focused biotech 🔬 Absci and AstraZeneca: A $247 million deal was announced in December 2023 to develop AI-designed anticancer antibodies. 🔬 BigHat Biosciences and AbbVie: A collaboration worth over $200 million to leverage AI for antibody development. 🔬 BigHat Biosciences and Almirall: A $610 million deal to create AI-designed therapeutics for dermatological diseases. 🔬 Sanofi and BioMap: A partnership potentially worth more than $1 billion to develop AI models for biological design. 🔬 Xaira Therapeutics, Co-founded by David Baker, is an AI-focused biotech that launched with over $1 billion in funding. It aims to use generative AI tools like diffusion models to design next-generation biologics. 🤝 These partnerships and innovations are not just significant; they are game-changers. They underscore the growing impact of AI in biotech, paving the way for faster and more efficient development of therapeutic antibodies. The integration of AI and biologics expertise is poised to revolutionize the industry, offering new hope for the treatment of various diseases. #artificalintelligence

Every week, our interactions with expert drug developers keep us plugged into the pulse of innovation. These conversations fuel our MicroSummits and help us bring the most relevant and impactful discussions to the forefront. This week we had several conversations with senior Biotech leaders in the complex Biologics space, with a particular focus on Antibody Drug Conjugates: 🦠 Enhanced Targeting Precision in ADCs - Recent advancements in ADC technology have led to improved targeting capabilities, allowing for more precise delivery of the therapeutic payload to cancer cells. This refinement in targeting reduces off-target effects and enhances the efficacy of the treatment, making ADCs a more precise tool in the fight against cancer. 🧬 Focus on Payloads in ADC Development - A significant trend in the ADC space is the focus on enhancing the payload, the component that delivers the therapeutic effect. Recent collaborations, such as those between Merck and Daiichi Sankyo, are a testament to this, with many companies now prioritizing advancements in payload technology for better efficacy and safety. 🌡️ Increased Safety in Newer ADCs - Modern ADCs are showing much higher Maximum Tolerated Doses (MTD) in clinical studies compared to earlier drug classes. This indicates a substantial improvement in the safety profile of ADCs, making them more viable for treating a wider range of conditions without severe toxicity concerns. Are you enthusiastic about meaningful discussions with your peers in drug developers? Get in touch to find out about speaker opportunities or join one of our upcoming sessions. Always free for drug developers. #adcs #Biotech #BiotechEvents #MicroSummits

Nature Biotech article on progress in Antibody Drug Conjugates (ADCs). I am an “ADC Geek” but did you know it has taken 24 years for the ADC modality to become an overnight success?!? The first ADC (Mylotarg) was approved in 2000 but the modality faced challenges around manufacturing especially in linking the antibody with the drug. Great to see the momentum in this exciting modality. https://lnkd.in/ehuhUC-h

Our CEO Maria Lisa Knudsen, PhD sat down for an interview with Scrip to talk about AAX Biotech and our exciting technologies, summarized nicely in this article “Ambitious AAX Wants To Be Key Player In Next-Generation Antibodies”:   “Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.   … AAX can boast not one but two technologies which both aim to produce more effective antibody-based medicines. The first is Opti-mAb which improves the stability and production of single- chain variable fragments (scFv), an antibody format used in CAR-T and bispecifics.   AAX's second technology is Seqitope, which the company says is an innovative method for antibody epitope mapping which yields high-resolution results while also being high throughput.”   Full article: https://lnkd.in/dw9kGYTd   Citeline Commercial #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment

Aragen is thrilled to participate in the 8th Annual IPF Summit in Boston, MA, on August 21-22, 2024, at booth no. 2. Aragen offers a comprehensive portfolio of in vivo, in vitro, and ex vivo fibrosis models, paired with world-class expertise in anti-fibrotic therapeutic development. Over the past decade, we've evaluated the efficacy of test compounds across various modalities—small molecules, biologics, RNA therapeutics, exosomes, and more—leading to successful IND submissions. Our specialized diet-induced, chemical-induced, and surgical fibrosis models and thorough disease parameter evaluations are crucial in advancing novel therapies. Notably, our bleomycin-induced pulmonary fibrosis (IPF) model is highly reproducible and has been instrumental in accelerating drug candidates beyond the preclinical phase, supporting both therapeutic and prophylactic developments. Click here https://lnkd.in/gFff_EP6 to schedule a meeting, today with our experts! Danielle Liu & Malavika Ghosh #vivo #invitro #exvivo #fibrosismodels #pulmonaryfibrosis #biologics #drugdevelopment #INDfiling #events2024 #CDMO #CRO #lifesciences #endtoendsolutions #therapeutics

𝐁𝐢𝐨𝐜𝐲𝐭𝐨𝐠𝐞𝐧 𝐚𝐧𝐝 𝐈𝐃𝐄𝐀𝐘𝐀 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐟𝐨𝐫 𝐅𝐢𝐫𝐬𝐭-𝐢𝐧-𝐂𝐥𝐚𝐬𝐬 𝐁𝟕𝐇𝟑/𝐏𝐓𝐊𝟕 𝐁𝐬𝐀𝐃𝐂 𝐏𝐫𝐨𝐠𝐫𝐚𝐦 Biocytogen Pharmaceuticals (HKEX: 02315) Biocytogen, a global biotech company focused on novel antibody/ADC therapeutics, has entered an option and license agreement with IDEAYA Biosciences, Inc. (Nasdaq: IDYA) IDEAYA Biosciences for a potential first-in-class B7H3/PTK7 BsADC program. Dr. Yuelei Shen Yuelei Shen, President and CEO of Biocytogen, stated, “This partnership leverages our RenLite® platform and proprietary linker-payload technology to enhance ADC precision and potency. IDEAYA's expertise in drug development makes us confident in advancing this therapy to benefit patients.” Yujiro S. Hata Yujiro S. H., CEO of IDEAYA, added, “This BsADC program, developed as a monotherapy for multiple solid tumors, aligns with our strategy to combine ADCs with DDR-based therapies for greater patient benefit.” The agreement grants IDEAYA an option for an exclusive worldwide license from Biocytogen for the B7H3/PTK7 BsADC program. Biocytogen will receive an upfront fee and, upon option exercise by IDEAYA, additional milestone payments and royalties. Total potential payments could reach $406.5 million, including $100 million in development and regulatory milestones. A development candidate nomination for the B7H3/PTK7 topoisomerase-I-inhibitor payload BsADC program is targeted for the second half of 2024. #Biotechnology #Pharmaceuticals #CancerResearch #ADCTherapeutics #Oncology #PrecisionMedicine #DrugDevelopment #Biocytogen #IDEAYA #Innovation #Healthcare #Partnership #LifeSciences

Thoughts on this? >> Nvidia's biotech moment; Regeneron launches venture arm; New GLP-1 player enters; Sanofi rejigs cancer pact, vaccine ops; and more >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical

Have you ever heard of covalent biologics? 🔗 The budding field of covalent biologics has made headway recently, as Enlaza Therapeutics has bagged $100 million in funding to move its pipeline to the clinic. 🏥 These drugs are meant to lock onto a target protein and form a lasting bond with it. This way cancer cells and inflammatory cells in autoimmune diseases can be targeted. 🎯 Labiotech spoke to Sergio Duron, CEO of preclinical company Enlaza, the only biotech involved in the space. Read our latest article to find out more about this new class of drugs! 👇 https://lnkd.in/dx7v5ZNF #covalentbiologics #biotech #healthcareinnovation #cancertherapy #autoimmunediseases #biotechfunding #pharmaceuticals #drugdevelopment #medicalresearch

We're thrilled to announce Dr. Tehila Ben Moshe's (Tehila Ben-Moshe) upcoming talk at the IO-360° (Immuno-Oncology 360) Conference, "INspire: An Intracellular delivery platform for biologics: Sending antibodies to bind intracellular targets" Discover how we're pushing the boundaries of biologic therapies by enabling antibodies to target intracellular pathways. 🗓️ Date: Tuesday, February 27, 2024 ⏰ Time: 04:10 PM - 04:30 PM 📍 Track: A - DISCOVERY, PRECLINICAL & PAYLOAD MODIFICATION (SALON E) 🏨 Venue: New York Marriott at the Brooklyn Bridge, 333 Adams Street, Brooklyn, New York 11201 Mark your calendars for this segment of the Payload Delivery & Modification Lightning Talks. It's an opportunity not to be missed for those passionate about the future of biologics in immuno-oncology. #IO360nyc #Biologics #IntracellularDelivery #BiotechInnovation #ScientificTalks #PayloadModification

It's fascinating how biotech continues to innovate. The potential for more targeted and less toxic cancer treatments with ADC is truly promising! #Biotechnology #Innovation #AntibodyDrugConjugates #CancerTherapy #Pharmaceuticals